Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab A/S (GMAB) Q1 2023 Earnings Conference Call May 10, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Conference Call Participants Michael Schmidt - Guggenheim Securities Peter Welford - Jefferies Emily Field - Barclays Bank Rajan Sharma - Goldman Sachs Group James Gordon - JPMorgan Chase & Co. Matthew Phipps - William Blair & Company Yaron Werber - TD Cowen Asthika Goonewardene - Truist Securities Peter Verdult - Citigroup Operator Hello, and welcome to the Genmab's First Quarter 2023 Financial Results Conference Call. As a reminder, this conference call is being recorded.

Genmab A/S (GMAB) Q1 2023 Earnings Call Transcript

May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023

Genmab Announces Financial Results for the First Quarter of 2023

Amphastar Pharma

Catalyst Pharmaceuticals

Genelux Corp

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank Most Stocks

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration.

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal dismissed Genmab's claims, on the basis that they should have been brought in the first arbitration.

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 2,264 million i n the first quarter of 202 3 . Net trade sales were USD 1,191 million in the U.S. and USD 1,072 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

argenx

Media Release COPENHAGEN, Denmark; April 1 7 , 2023 Genmab and  argenx   have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway    Genmab A/S  (Nasdaq: GMAB) and argenx  (Euronext & Nasdaq: ARGX) announced today that Genmab and  argenx  have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology , as well as i n oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Media Release COPENHAGEN , Denmark; March 28 , 20 23

Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Matthew Harrison - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Jonathan Chang - SVB Securities Elizabeth Walton - Crédit Suisse AG Paul Jeng - Guggenheim Securities Yaron Werber - Cowen and Company Emily Field - Barclays Asthika Goonewardene - Truist Securities, Inc Etzer Darout - BMO Capital Markets Matthew Phipps - William Blair & Company Operator Hello, and welcome to the Genmab Full-year 2022 Conference Call. As a reminder, this conference call is being recorded.

Genmab A/S (GMAB) Q4 2022 Earnings Call Transcript

Genmab Publishes 2022 Annual Report

Hologic

ServiceNow

Splunk

These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).

4 Top Stocks to Buy on Earnings Beat Potential

Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022.

Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

Gilead Sciences

GILD vs. GMAB: Which Stock Is the Better Value Option?

GILD or GMAB: Which Is the Better Value Stock Right Now?

Correction to Company Announcement No. 1 of January 3, 2023

United Therapeutics

Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof.

3 Biotech Companies to Watch in 2023

Media Release COPENHAGEN, Denmark ; January 2 , 20 2 3 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41 st  Annual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12 :00 PM EST / 6 : 00 PM CET on January 11, 2023. The live and archived webcast of the presentation will be available on Genmab's website at  https://ir.genmab.com/events-and-presentations#content .

Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

Inspire Medical Systems Inc

Medpace Holdings

These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close appeared first on Investor's Business Daily.

Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close

Ambac Financial Group

Comstock Resources

HF Sinclair Corp

Graphic Packaging Hld

Hess

Murphy Oil

NVIDIA

Occidental Petroleum

Pinduoduo Inc - ADR

Phillips 66

TotalEnergies SE

Valero Energy

Oil stocks dominate this list of today's fastest-growing stocks, all eyeing 100%-1,220% EPS gains this year. The post With Bear Market Scars, These 26 Stocks Expect Up To 1,220% Growth appeared first on Investor's Business Daily.

With Bear Market Scars, These 26 Stocks Expect Up To 1,220% Growth

COPENHAGEN, Denmark--( BUSINESS WIRE )--Genmab A/S (Nasdaq: GMAB):

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Ligand Pharmaceuticals

LGND vs. GMAB: Which Stock Is the Better Value Option?

LGND or GMAB: Which Is the Better Value Stock Right Now?

Genmab to Hold 2022 R&D Update and ASH Data Review Meeting

News for Genmab - ADR Stock (GMAB)